Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Anna Jonasova"'
Autor:
Anna Jonasova, Slavka Sotakova, Petra Belohlavkova, Lubomir Minarik, Tomas Stopka, Jan Jakub Jonas, Tatiana Aghova, Zuzana Zemanova
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundLuspatercept, an inhibitor of the transforming growth factor beta (TGF-β) pathway, is a novel treatment for anemic patients with lower-risk myelodysplastic syndromes (MDS) with transfusion dependence (TD) who do not respond to erythropoies
Externí odkaz:
https://doaj.org/article/247a1b3de16f41069ac9525bde74c80a
Autor:
Iva Trsova, Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Aleš Holoubek, Karolina Staflova, Lucie Janstova, Sarka Vanikova, Katarina Szikszai, Jiri Klema, Petr Rysavy, Monika Belickova, Monika Kaisrlikova, Jitka Vesela, Jaroslav Cermak, Anna Jonasova, Jiri Dostal, Jan Fric, Jan Musil, Michaela Dostalova Merkerova
Publikováno v:
Molecular Oncology, Vol 17, Iss 12, Pp 2565-2583 (2023)
Mutations in the splicing factor 3b subunit 1 (SF3B1) gene are frequent in myelodysplastic neoplasms (MDS). Because the splicing process is involved in the production of circular RNAs (circRNAs), we investigated the impact of SF3B1 mutations on circR
Externí odkaz:
https://doaj.org/article/cf124e1e1eda474f8d617a5629fc916b
Autor:
Miroslav Pribyl, Sona Hubackova, Alena Moudra, Marketa Vancurova, Helena Polackova, Tomas Stopka, Anna Jonasova, Radka Bokorova, Ota Fuchs, Jan Stritesky, Barbora Salovska, Jiri Bartek, Zdenek Hodny
Publikováno v:
Molecular Oncology, Vol 14, Iss 10, Pp 2403-2419 (2020)
Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone ma
Externí odkaz:
https://doaj.org/article/fb9c612ae072482e8ba012c2ca32f842
Autor:
Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Katarina Szikszai, Monika Belickova, Pavla Pecherkova, Jiri Klema, Jitka Vesela, Monika Hruba, Jaroslav Cermak, Tereza Hrdinova, Matyas Krijt, Jan Valka, Anna Jonasova, Michaela Dostalova Merkerova
Publikováno v:
Cells, Vol 9, Iss 4, p 794 (2020)
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders with large heterogeneity at the clinical and molecular levels. As diagnostic procedures shift from bone marrow biopsies towards less invasive techniques, circulating small noncodin
Externí odkaz:
https://doaj.org/article/6694200bbc214c129172b7000b61d9f9
Autor:
Michaela Dostalova Merkerova, Hana Remesova, Zdenek Krejcik, Nikoleta Loudova, Andrea Hrustincova, Katarina Szikszai, Jaroslav Cermak, Anna Jonasova, Monika Belickova
Publikováno v:
Cells, Vol 7, Iss 9, p 138 (2018)
The DLK1–DIO3 region contains a large miRNA cluster, the overexpression of which has previously been associated with myelodysplastic syndromes (MDS). To reveal whether this overexpression is epigenetically regulated, we performed an integrative ana
Externí odkaz:
https://doaj.org/article/db4f5dfe21ed4b1bbfe2ccc30bd0d202
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e87448 (2014)
CCCTC-binding factor (CTCF) can both activate as well as inhibit transcription by forming chromatin loops between regulatory regions and promoters. In this regard, Ctcf binding on non-methylated DNA and its interaction with the Cohesin complex result
Externí odkaz:
https://doaj.org/article/3479aeba3d50472eb8a86377b47560a4
Publikováno v:
Case Reports in Hematology, Vol 2012 (2012)
Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper ou
Externí odkaz:
https://doaj.org/article/162425a9b2bc4a60bddc8f6047ef6ab8
Autor:
Monika Kaisrlikova, Jitka Vesela, David Kundrat, Hana Votavova, Michaela Dostalova Merkerova, Zdenek Krejcik, Vladimir Divoky, Marek Jedlicka, Jan Fric, Jiri Klema, Dana Mikulenkova, Marketa Stastna Markova, Marie Lauermannova, Jolana Mertova, Jacqueline Soukupova Maaloufova, Anna Jonasova, Jaroslav Cermak, Monika Belickova
Publikováno v:
Leukemia. 36:1898-1906
Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, a small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive of LR-MDS progression and to uncover c
Autor:
Michaela Dostalova, Merkerova, Jiri, Klema, David, Kundrat, Katarina, Szikszai, Zdenek, Krejcik, Andrea, Hrustincova, Iva, Trsova, Anh Vu, LE, Jaroslav, Cermak, Anna, Jonasova, Monika, Belickova
Publikováno v:
Cancer Genomics Proteomics
Background/Aim: Prediction of response to azacitidine (AZA) treatment is an important challenge in hematooncology. In addition to protein coding genes (PCGs), AZA efficiency is influenced by various noncoding RNAs (ncRNAs), including long ncRNAs (lnc
Autor:
Anne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, Anna Jonasova, Regina Herbst, Jose Miguel Torregrosa Diaz, Benoit De Renzis, Katharina S. Götze, Marie-Luise Huetter-Kroenke, Marie-Pierre Gourin, Borhane Slama, Sophie Dimicoli-Salazar, Pascale Cony-Makhoul, Kamel Laribi, Sophie Park, Katja Jersemann, Dorothea Schipp, Klaus H. Metzeler, Oliver Tiebel, Katja Sockel, Silke Gloaguen, Anna Mies, Fatiha Chermat, Christian Thiede, Rosa Sapena, Richard F. Schlenk, Pierre Fenaux, Uwe Platzbecker, Lionel Adès
Publikováno v:
Leukemia.
The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within the ‘European M